PMID- 11161986
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20231213
IS  - 1521-6616 (Print)
IS  - 1521-6616 (Linking)
VI  - 98
IP  - 2
DP  - 2001 Feb
TI  - Replicative response, immunophenotype, and functional activity of 
      monocyte-derived versus CD34(+)-derived dendritic cells following exposure to 
      various expansion and maturational stimuli.
PG  - 280-92
AB  - Dendritic cells (DCs), generated ex vivo from blood mononuclear cells (PBMC) or 
      CD34(+) stem cells, are being used to develop novel immunotherapies. To establish 
      optimal DC generation, a direct comparison of the optimal cell source, culture 
      conditions, and maturation stimuli was performed, utilizing phenotypic and 
      functional assays as end points. Plastic adherent monocytes from PBMC were 
      expanded in a serum-free medium (X-Vivo 10) for 7 days using GM-CSF/IL-4; CD34(+) 
      cells were expanded for 14 days using GM-CSF/IL-4/ Flt3L, in either X-Vivo 10 
      alone or with albumin or autologous plasma. Expanded DC from both cell sources 
      were matured for 7 days with CD40L or IFN-alpha/TNF-alpha. Starting from 2 x 
      10(7) monocytes, the optimal expansion/maturation process yielded 1.73 +/- 0.52 x 
      10(6) CD86(+) DC. Optimal expansion of CD34(+) cells (83.9 +/- 25.0-fold) was 
      achieved using X-Vivo 10 with 5% plasma, matured with CD40L, and yielded 10.68 
      +/- 2.72 x 10(6) CD86(+) DC from 1 x 10(6) CD34(+) cells. Mature DC from PBMC or 
      CD34(+) cells had similar enhanced expression of MHC class II HLA-DR, CD80, CD83, 
      and CD86 and were potent stimulators of mixed lymphocyte reactions. Prior to 
      maturation, all groups of DC actively phagocytosed apoptotic melanoma cells 
      (approximately 50% of HLA-DR(+)). CD34(+) DC matured with CD40L or 
      IFN-alpha/TNF-alpha had reduced phagocytic capability (34 and 31% of HLA-DR(+) 
      DC, respectively). Similar expansion and functional activity was found using 
      cryopreserved DC precursors, cultured in gas permeable bags. We conclude that 
      both cell lineages produce potent mature DC, permitting exploration of the 
      optimal clinical strategy to trigger anti-tumor immune responses in patients with 
      malignancies.
CI  - Copyright 2000 Academic Press.
FAU - Chen, B
AU  - Chen B
AD  - Department of Medicine, Cardinal Bernardin Cancer Center, Maywood, Illinois, 
      60153-5385, USA.
FAU - Stiff, P
AU  - Stiff P
FAU - Sloan, G
AU  - Sloan G
FAU - Kash, J
AU  - Kash J
FAU - Manjunath, R
AU  - Manjunath R
FAU - Pathasarathy, M
AU  - Pathasarathy M
FAU - Oldenburg, D
AU  - Oldenburg D
FAU - Foreman, K E
AU  - Foreman KE
FAU - Nickoloff, B J
AU  - Nickoloff BJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD34)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD86 protein, human)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interferon-alpha)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (flt3 ligand protein)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 147205-72-9 (CD40 Ligand)
RN  - PVI5M0M1GW (Filgrastim)
SB  - IM
MH  - Antigens, CD/biosynthesis/genetics
MH  - Antigens, CD34/analysis
MH  - B7-1 Antigen/biosynthesis/genetics
MH  - B7-2 Antigen
MH  - CD40 Ligand/pharmacology
MH  - Cell Differentiation/drug effects
MH  - Cell Division/drug effects
MH  - Cell Lineage
MH  - Cells, Cultured
MH  - Dendritic Cells/chemistry/cytology/*drug effects/physiology
MH  - Filgrastim
MH  - Gene Expression Regulation/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Genes, MHC Class II
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - HLA-DR Antigens/biosynthesis
MH  - Hematopoietic Stem Cell Mobilization
MH  - Hematopoietic Stem Cells/*cytology/drug effects
MH  - Humans
MH  - Immunoglobulins/biosynthesis/genetics
MH  - Immunophenotyping
MH  - Interferon-alpha/pharmacology
MH  - Leukapheresis
MH  - Lymphocyte Culture Test, Mixed
MH  - Lymphoma, Non-Hodgkin/blood
MH  - Membrane Glycoproteins/biosynthesis/genetics
MH  - Membrane Proteins/pharmacology
MH  - Monocytes/*cytology/drug effects
MH  - Multiple Myeloma/blood
MH  - Phagocytosis/drug effects
MH  - Recombinant Proteins/pharmacology
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - CD83 Antigen
EDAT- 2001/02/13 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S1521-6616(00)94968-4 [pii]
AID - 10.1006/clim.2000.4968 [doi]
PST - ppublish
SO  - Clin Immunol. 2001 Feb;98(2):280-92. doi: 10.1006/clim.2000.4968.